Psych MEQs / SAQs · Psychopharmacology — clozapine
Initiating clozapine in treatment-resistant schizophrenia (MEQ)
FRANZCP-style MEQ on clozapine entry criteria, initiation, monitoring, smoking interaction, and CIGH prevention.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) TRRIP and offer. Treatment-resistant schizophrenia: confirmed schizophrenia-spectrum diagnosis; inadequate response to at least two different antipsychotics at adequate dose and duration with adherence confirmed; exclude pseudo-resistance (substances, under-dosing, non-adherence, organic mimics). Kane established clozapine superiority in TRS; Siskind meta-analyses support meaningful response rates and earlier use. Offer clozapine with full monitoring — not endless non-clozapine polypharmacy. Mention InterSePT if suicide risk is prominent.[1][2][3][7]
(ii) Pre-start. FBC/ANC, metabolic panel, weight/BMI/waist, ECG, CRP ± troponin per local myocarditis protocol, U&E/LFT, pregnancy test if relevant, smoking history, medication review (avoid carbamazepine; caution fluvoxamine). Confirm registry enrolment and that the team can obtain protocol bloods and act on red results. Shared decision with honest risk–benefit counselling.[4]
(iii) Titration and first month. Start 12.5 mg; slow stepwise rise over days–weeks toward an individualised adult target often in the 200–450 mg/day range. First-month cardiac vigilance: fever, unexplained tachycardia, chest pain → stop and investigate myocarditis (ECG, CRP, troponin, cardiology). Haematology per local schedule (commonly weekly early). Metabolic and bowel monitoring from day one.[4]
(iv) Smoking and levels. Cigarette smoking induces CYP1A2 and lowers clozapine levels; smokers often need higher doses; cessation raises levels and toxicity risk — plan level checks and possible dose reduction if he stops smoking. If non-response at adequate dose, check trough level (classic teaching ~0.35 mg/L / 350 ng/mL as a response threshold scaffold) and individualise.[5]
(v) Constipation/CIGH. Proactive laxative protocol and bowel chart from initiation. Teach red flags: severe constipation, vomiting, distension, no flatus. Escalation: stop clozapine, surgical review — life-threatening hypomotility is documented in large series.[6]
Common errors
- Declaring resistance after non-adherent micro-doses rather than TRRIP-adequate trials.[1]
- Starting without monitoring capacity or registry pathway.[4]
- Ignoring first-month myocarditis symptoms as "viral".[4]
- Forgetting smoking cessation as a toxicity risk on the ward.[5]
- Treating constipation as trivial PRN advice only.[6]
References
- [1]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182
- [2]Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 1988.PMID 3046553
- [3]Siskind D, Siskind V, Kisely S Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis Can J Psychiatry, 2017.PMID 28655284
- [4]Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry, 2010.PMID 20361910
- [5]Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 2004.PMID 14709950
- [6]Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry, 2008.PMID 18452342
- [7]Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 2003.PMID 12511175